MannKind Corp Files 8-K with Material Agreement

TL;DR

MannKind signed a big deal, filing an 8-K. Details to follow.

AI Summary

On August 24, 2025, MannKind Corporation entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this excerpt.

Why It Matters

This filing indicates a significant new development or contract for MannKind Corporation, which could impact its business operations and financial future.

Risk Assessment

Risk Level: medium — The filing of a material definitive agreement suggests a significant event, but the lack of specific details in this excerpt introduces uncertainty.

Key Numbers

• 000-50865 — SEC File Number (Identifies the specific filing with the SEC.)
• 13-3607736 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• MannKind Corporation (company) — Registrant
• August 24, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 1 Casper Street, Danbury, Connecticut 06810 (address) — Principal Executive Offices
• (818) 661-5000 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
• $0.0001 — of the Target's common stock, par value $0.0001 per share (the " Target Shares "), at a
• $5.35 — Shares "), at a price per share of (i) $5.35 in cash (the " Cash Amount "), without
• $1.00 — stone payments of up to an aggregate of $1.00 in cash. If successful, upon the terms
• $9.48 million — d to pay to Parent a termination fee of $9.48 million. In addition, either the Target or Pare
• $0.75 — , such milestone, " Milestone 1 "), (a) $0.75 per CVR if Milestone 1 is achieved by S
• $0.50 — is achieved by September 30, 2026, (b) $0.50 per CVR if Milestone 1 is achieved by D
• $0.25 — s achieved by December 31, 2026 and (c) $0.25 per CVR if Milestone 1 is achieved by J
• $110.0 million — Milestone 2 Outside Date ") of at least $110.0 million of worldwide net sales of all Injection
• $120.0 million — ) $0.25 per CVR upon the achievement of $120.0 million of worldwide net sales in any trailing
• $0.10 — or to December 31, 2026 and (b) between $0.10 and $0.25 per CVR if, as of December 31
• $120.0 m — period were between $110.0 million and $120.0 million, which payment will be calculated
• $175.0 million — Lenders agreed to provide an additional $175.0 million incremental delayed draw term loan sole
• $75.0 million — recedent to Parent's borrowing of up to $75.0 million of delayed draw term loans (out of the
• $125.0 million — d draw term loans (out of the aggregate $125.0 million in delayed draw term loan commitments a

Filing Documents

• d931701d8k.htm (8-K) — 67KB
• d931701dex21.htm (EX-2.1) — 699KB
• d931701dex101.htm (EX-10.1) — 71KB
• d931701dex102.htm (EX-10.2) — 1010KB
• d931701dex991.htm (EX-99.1) — 34KB
• d931701dex992.htm (EX-99.2) — 19KB
• g931701ex99_2s10g1.jpg (GRAPHIC) — 79KB
• g931701ex99_2s11g1.jpg (GRAPHIC) — 68KB
• g931701ex99_2s12g1.jpg (GRAPHIC) — 72KB
• g931701ex99_2s13g1.jpg (GRAPHIC) — 95KB
• g931701ex99_2s14g1.jpg (GRAPHIC) — 135KB
• g931701ex99_2s15g1.jpg (GRAPHIC) — 61KB
• g931701ex99_2s1g1.jpg (GRAPHIC) — 83KB
• g931701ex99_2s2g1.jpg (GRAPHIC) — 218KB
• g931701ex99_2s3g1.jpg (GRAPHIC) — 235KB
• g931701ex99_2s4g1.jpg (GRAPHIC) — 76KB
• g931701ex99_2s5g1.jpg (GRAPHIC) — 79KB
• g931701ex99_2s6g1.jpg (GRAPHIC) — 85KB
• g931701ex99_2s7g1.jpg (GRAPHIC) — 106KB
• g931701ex99_2s8g1.jpg (GRAPHIC) — 109KB
• g931701ex99_2s9g1.jpg (GRAPHIC) — 89KB
• g931701g0825014908210.jpg (GRAPHIC) — 2KB
• 0001193125-25-186994.txt ( ) — 4684KB
• mnkd-20250824.xsd (EX-101.SCH) — 3KB
• mnkd-20250824_lab.xml (EX-101.LAB) — 17KB
• mnkd-20250824_pre.xml (EX-101.PRE) — 11KB
• d931701d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will", "goal" and similar expressions. These forward-looking statements include, without limitation, statements related to the proposed Offer, Merger and related transactions contemplated by the Merger Agreement and the CVR Agreement and the expected timing thereof; the expected benefits from the acquisition of FUROSCIX, including diversifying and accelerating double-digit revenue growth goals over the next decade, Parent emerging as a patient-centric leader in cardiometabolic and lung diseases, strengthening Parent's organization and revenue base and the potential synergies; the belief that the acquisition will accelerate access to important therapies and create meaningful value for patients, providers, and stockholders; the estimated aggregate repayment and buyout amount to repay and extinguish all outstanding indebtedness of Target under its credit facility with Perceptive and buy-out Perceptive's rights to receive revenue payments pursuant to its revenue purchase and sale agreement upon the closing of the transaction; Parent's strategy to expand into cardiorenal medicine; Parent's anticipated product launches and indication expansions and the expected benefits therefrom; the development plan for FUROSCIX, including the timing for an supplemental New Drug Application submission of the FUROSCIX autoinjector in the third quarter 2025; the potential benefits and market opportunity for FUROSCIX; Parent's potential to expand market reach in the U.S. and globally; the upcoming data readouts for Parent's TETON 1 and 2 studies of Tyvaso in idiopathic pulmonary fibrosis; Parent's ability to effectively support the recent chronic kidney disease approval of FUROSCIX and accelerate its market opportunity; Parent's expectation to continue FUROSCIX's ongoing succe

View Full Filing

View this 8-K filing on SEC EDGAR